Literature DB >> 8084530

Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.

J Rataud1, F Debarnot, V Mary, J Pratt, J M Stutzmann.   

Abstract

This study evaluates the neuroprotective properties of some voltage-sensitive sodium channel blockers in a model of focal ischaemia. After curative treatment (0.5 and 24.5 h after insult), well known voltage-sensitive sodium channel blockers, phenytoin (2 x 100 mg/kg i.p.), carbamazepine (2 x 50 mg/kg i.p.), lamotrigine (2 x 50 mg/kg i.p.) and RP 66055 (2 x 8 mg/kg i.p.) were found to protect rats against brain damage induced by occlusion of the middle cerebral artery, by 40%, 24%, 28% and 44% respectively. These compounds were also active in protecting both mice and rats against tonic convulsions induced by electroshock, Intraperitoneal ED50 values in mice and rats respectively were of 5.2 and 12.5 mg/kg for phenytoin, 8.4 and 3.6 mg/kg for carbamazepine, 4.4 and 3.1 mg/kg for lamotrigine, 3.9 and 0.22 mg/kg for RP 66055. In contrast, lifarizine was totally devoid of activity in these three tests. This study extends an accumulation of data in the literature pointing to a therapeutic potential for voltage-dependent sodium channel blockers which penetrate the blood brain barrier. Such compounds as phenytoin, carbamazepine, lamotrigine or RP 66055 may act at sodium channels to prevent depolarization, inhibit release of neurotransmitters such as glutamate and thus protects the cortex against cellular damage induced by focal ischaemia by both pre- and post-synaptic inhibition of abnormal neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8084530     DOI: 10.1016/0304-3940(94)90652-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

Review 1.  The search for neuroprotective strategies in stroke.

Authors:  Gary H Danton; W Dalton Dietrich
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

2.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain.

Authors:  Petra Bittigau; Marco Sifringer; Kerstin Genz; Ellen Reith; Dana Pospischil; Suresh Govindarajalu; Mark Dzietko; Stefanie Pesditschek; Ingrid Mai; Krikor Dikranian; John W Olney; Chrysanthy Ikonomidou
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

3.  Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder.

Authors:  Epolia Ramadan; Mireille Basselin; Jagadeesh S Rao; Lisa Chang; Mei Chen; Kaizong Ma; Stanley I Rapoport
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

4.  Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis.

Authors:  J K Callaway; P M Beart; B Jarrott; S F Giardina
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine.

Authors:  M C Walker; X Tong; H Perry; M S Alavijeh; P N Patsalos
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release.

Authors:  P C Waldmeier; P Wicki; W Fröstl; H Bittiger; J J Feldtrauer; P A Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

7.  The sodium channel blocker RS100642 reverses down-regulation of the sodium channel alpha-subunit Na(v) 1.1 expression caused by transient ischemic brain injury in rats.

Authors:  C Yao; A J Williams; X-C M Lu; R A Price; B S Cunningham; R Berti; F C Tortella; J R Dave
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

9.  Spotlight on lamotrigine in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 10.  Lamotrigine: a review of its use in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.